Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis

International Journal of Pharmaceutics

Volumn 401, Issue 1-2, 2010, Pages 93-102

  Agrawal, Yogeeta ^a   Petkar, Kailash C ^a   Sawant, Krutika K ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Acitretin; Clinical studies; Nanostructured lipid carriers; Psoriasis; Topical gel

Indexed keywords

CARBOMER; CARBOPOL 934; ETRETIN; GLYCEROL PALMITOSTEARATE; NANOMATERIAL; SOLVENT;

ARTICLE; CADAVER; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIARRHEA; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; FACTORIAL DESIGN; FREEZE DRYING; GEL; HEADACHE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER TOXICITY; NAUSEA; PARTICLE SIZE; PRIORITY JOURNAL; PSORIASIS; SKIN IRRITATION; TECHNIQUE; TREATMENT DURATION; X RAY DIFFRACTION; ZETA POTENTIAL;

ACITRETIN; ADMINISTRATION, CUTANEOUS; ADULT; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; GELS; HUMANS; LIPIDS; MALE; MIDDLE AGED; NANOSTRUCTURES; PARTICLE SIZE; PSORIASIS; SKIN ABSORPTION; X-RAY DIFFRACTION;

EID: 78049316339     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.09.007     Document Type: Article

References (35)

1. Allen J.G., Bloxham D.P. The pharmacology and pharmacokinetics of retinoids. Pharmacol. Ther. 1989, 40:1-27.
2. British Pharmacopoeia, 2001. The British Pharmacopoeia Secretariat, London, UK.
3. Christophers E. Psoriasis epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26:314-320.
4. Feste, J.V., 1999. Lipid nanopartikel ais tragersystem for die dermale Applikation von retinol (English version). PhD Thesis. Free University of Berlin, Germany.
5. Gordon K.B., Papp K.A., Hamilton T.K. Psoriasis: a randomized controlled trial. JAMA 2003, 290:3073-3080.
6. Hsia E., Johnston M.J., Houlden R.J., Chern W.H., Hofland H.E. Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse. J. Invest. Dermatol. 2008, 128:125-130.
7. Hu F.Q., Yuan H., Zhang H.H., Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 2002, 239:121-128.
8. Indian Pharmacopoeia, 1996. The Controller of Publications, Government of India, Delhi, India.
9. Jenning V., et al. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49:211-218.
10. Jenning V., Gohla S.H. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencapsul. 2001, 18:149-158.
11. Jenning V., Gysler A., Schäfer-Korting M., Gohla S.H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49:211-218.
12. Jenning V., Schafer-Korting M., Gohla S. Vitamin A loaded solid lipid nanoparticles for topical application: drug release properties. J. Control Rel. 2000, 66:115-126.
13. Jenning V., Thünemann A.F., Gohla S.H. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000, 199:167-177.
14. Kalariya M., Misra A.N. Methotrexate-loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation and clinical implications. AAPS Pharm. Sci. Technol. 2004, 4:225-241.
15. Kaur I., Handa S., Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J. Dermatol. 1997, 24:230-234.
16. Komatsu H., Kitajima A., Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem. Pharm. Bull. (Tokyo) 1995, 43:1412-1415.
17. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch. Dermatol. 2001, 137:280-284.
18. Küchler S., Herrmann W., Panek-Minkin G., Kramer K.D., Bittl R., Schäfer-Korting M. SLN for topical application in skin diseases - characterization of drug-carrier and carrier-target interactions. Int J Pharm. 2010, 390:225-233.
19. Lee C.S., Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin. Pharmacother. 2005, 6:1725-1734.
20. Liu J., Hu W., Chen H., Ni Q., Xu H., Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328:191-195.
21. Lombardi B.S., et al. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 2005, 110:151-163.
22. Lynda Sutton B.S. A clinical study to determine the efficacy and safety of 1% methotrexate/azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int. J. Dermatol. 2001, 40:464-467.
23. Maia S.C., Mehnert W., Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm. 2000, 196:165-167. (triethanolamine).
24. Maia C., Mehnert W., Schaller M., Korting H.C., Gysler A., Haberland A., Scḧafer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Target. 2002, 10:489-495.
25. ®) for oral drug delivery. Drug Dev. Ind. Pharm. 2008, 34:1394-1405.
26. Mehta A.K., Yadav K.S., Sawant K.K. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr. Drug Deliv. 2007, 4:185-193.
27. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
28. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 23:3-19.
29. Müller R.H., Dingler A. The next generation after the liposomes: solid lipid nanoparticles (SLNTM LipopearlsTM) as dermal carrier in cosmetics. Eurocosmetics 1998, 7:19-26.
30. Pople P.V., Singh K.K. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS Pharm. Sci. Technol. 2006, 7:E1-E7.
31. Reddy H.L., Murthy R.S.R. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharm. Sci. Technol. 2005, 6:E158-166.
32. Sarmento B, Ferreira D., Veiga V., Ribeiro A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr. Polym. 2006, 66:1-7.
33. Shah K.A., Date A.A. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int. J. Pharm. 2007, 345:163-171.
34. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278:71-77.
35. Westesen K., Siekmann B., Koch M.H.J. Investigation on the physical state of lipid nanoparticles by synchrotron X-ray diffraction. Int. J. Pharm. 1993, 93:189-199.